Literature DB >> 15204485

Non-surgical management of ankle contracture following acquired brain injury.

B J Singer1, J W Dunne, K P Singer, G M Jegasothy, G T Allison.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to document the outcome of non-surgical management of equinovarus ankle contracture in a cohort of patients with acquired brain injury admitted to a specialist Neurosurgical Rehabilitation Unit.
METHODS: This prospective descriptive study examined all patients with a new diagnosis of moderate to severe acquired brain injury (Glasgow Coma Scale score </=12) admitted for rehabilitation over a 1 year period. Ankle dorsiflexion range and plantarflexor/invertor muscle activity were evaluated weekly during the period of hospitalization. Contracture was defined as maximal passive range of motion </= 0 degrees dorsiflexion, with the knee extended, on a minimum of two measurement occasions. Patients were retrospectively allocated to one of four treatment outcome categories according to ankle dorsiflexion range, type of intervention required and response to treatment.
RESULTS: Ankle contracture was identified in 40 of the 105 patients studied. Contracture resolved with a standard physiotherapy treatment programme, including prolonged weight-bearing stretches and motor re-education, in 23 patients. Contracture persisted or worsened in 17 of 40 cases, all of whom exhibited dystonic muscle overactivity producing sustained equinovarus posturing. Ten of 17 cases required serial plaster casting (+/- injection of botulinum toxin type A) in order to achieve a functional range of ankle motion. Remediation of ankle contracture was not considered a priority in the remaining seven patients due to the severity of their overall disability.
CONCLUSION: The incidence of ankle contracture identified in this population was considerably less than previously reported. Reduced dorsiflexion range was remediated with standard physiotherapy treatment in over half of the cases. Additional treatment with serial casting +/- botulinum toxin type-A injection was required to correct persistent or worsening contracture in one quarter of cases. Dystonic extensor muscle overactivity was a major contributor to persistent or progressive ankle contracture.

Entities:  

Mesh:

Year:  2004        PMID: 15204485     DOI: 10.1080/0963828032000174070

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  6 in total

1.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

2.  Joint contracture following prolonged stay in the intensive care unit.

Authors:  Heidi Clavet; Paul C Hébert; Dean Fergusson; Steve Doucette; Guy Trudel
Journal:  CMAJ       Date:  2008-03-11       Impact factor: 8.262

3.  Quantitative analysis of the reversibility of knee flexion contractures with time: an experimental study using the rat model.

Authors:  Guy Trudel; Hans K Uhthoff; Louis Goudreau; Odette Laneuville
Journal:  BMC Musculoskelet Disord       Date:  2014-10-07       Impact factor: 2.362

4.  The effect of adding TENS to stretch on improvement of ankle range of motion in inactive patients in intensive care units: a pilot trial.

Authors:  MohammadBagher Shamsi; Aliakbar Vaisi-Raygani; Asghar Rostami; Maryam Mirzaei
Journal:  BMC Sports Sci Med Rehabil       Date:  2019-08-15

Review 5.  Systematic review and clinical recommendations for dosage of supported home-based standing programs for adults with stroke, spinal cord injury and other neurological conditions.

Authors:  Ginny Paleg; Roslyn Livingstone
Journal:  BMC Musculoskelet Disord       Date:  2015-11-17       Impact factor: 2.362

6.  Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study.

Authors:  Young-Ho Lim; Eun-Hi Choi; Jong Youb Lim
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.